周四（7月17日）中午，中国生物制药（01177.HK）股价盘中大涨7.3%，引发市场关注。该公司股价走强主要受以下因素推动：
近日，中国生物制药公告称，公司拟以不超过9.51亿美元（约合人民币68.22亿元）收购礼新医药95.09%股权。加上此前持有的4.91%股权，交易完成后礼新医药将成为中国生物制药全资子公司。礼新医药是一家专注于肿瘤免疫及肿瘤微环境领域的创新药研发公司，拥有多个具有全球同类首创或同类最优潜力的创新药物。此次收购将显著扩充中国生物制药的创新药管线，尤其是在肿瘤领域的研发实力。
分析人士认为，这笔收购展现了中国生物制药在创新药领域的战略布局，有望进一步增强公司的核心竞争力和国际影响力。市场对这一战略举措反应积极，推动了公司股价的强劲上涨。投资者普遍看好此次收购将为中国生物制药带来长期增长动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.